Fewer injections of botulinum toxin type A for treatment of spasticity are perceived as beneficial by both patients and caregivers.

2019-03-06T17:52:50+00:00 March 6th, 2019|News, Publications|

  • Presented at TOXINS 2019

  • Collaborator: Ipsen

  • Authors: Wein T, Patel A, Bahroo L, Wilczynski O, Rios C, Murie-Fernandez M

Botulinum toxin type A (BoNT-A) is a recommended pharmacological option for patients with spasticity, and its anti-spastic effects have been demonstrated in stroke and central nervous system lesions, multiple sclerosis and cerebral palsy. The aim of this study is to understand the impact of fewer BoNT-A injections from patient and caregiver perspectives.